PFS was better but from the tone of the news I assume not significant enough to justify any further trials.
Correct. This is not a hugely important indication from a commercial standpoint because there are relatively few NSCLC patients left by the time they have failed two or more other treatments.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.